Stem cell revolution: bridging the gap between research and clinical application

Stem cells are characterized by their capacity for self-renewal and their potential for multi-directional differentiation, enabling them to develop into various functional tissues and organs under specific conditions. Their applications hold considerable promise, and the market for stem cell products is progressively expanding. Internationally, several stem cell products have received approval for market release; however, in China, the field remains largely undeveloped, presenting substantial opportunities for growth. Recent years have witnessed significant advancements in stem cell research, driven by improvements in national policies, regulatory frameworks, and ongoing technological innovations. This progress has resulted in notable breakthroughs in basic science, as well as substantial advancements in clinical trials and industrial applications. Compared to previous decades, stem cell therapies in China have experienced remarkable progress, with numerous companies advancing to the clinical research phase, indicating a robust overall development trajectory. Nonetheless, the considerable variability in the sources, types, and preparation processes of stem cell products contributes to the complexity of their therapeutic mechanisms and in vivo activities, which are more intricate than those of traditional pharmaceuticals. Consequently, stem cell therapies encounter several challenges in drug development, including issues related to safety, induction efficiency, the exploration of clinical translation processes, and elevated research and development costs, all of which may hinder the advancement of stem cell therapies. Nevertheless, numerous companies and research institutions are actively engaged in promoting progress within the stem cell domain. It is anticipated that, as the stem cell sector continues to evolve, these challenges will be addressed, ultimately serving as a crucial catalyst for meeting various unmet clinical needs and effecting transformative changes in human healthcare and other sectors.

Authors

Institutions

Publication Details

Journal
Stem Cell Research & Therapy
Published
2025-11-26
DOI
https://doi.org/10.1186/s13287-025-04784-7
Citations
1
Primary Topic
Biomedical Ethics and Regulation
Type
article
Field-Weighted Citation Impact
1.16

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Stem cell revolution: bridging the gap between research and clinical application

Fengfeng Li, Chen Fu
1 citations
Stem Cell Research & Therapy
Biomedical Ethics and Regulation
1.16
article

Stem cell revolution: bridging the gap between research and clinical application

Fengfeng Li, Chen Fu
article en
1 citations

Abstract

Stem cells are characterized by their capacity for self-renewal and their potential for multi-directional differentiation, enabling them to develop into various functional tissues and organs under specific conditions. Their applications hold considerable promise, and the market for stem cell products is progressively expanding. Internationally, several stem cell products have received approval for market release; however, in China, the field remains largely undeveloped, presenting substantial opportunities for growth. Recent years have witnessed significant advancements in stem cell research, driven by improvements in national policies, regulatory frameworks, and ongoing technological innovations. This progress has resulted in notable breakthroughs in basic science, as well as substantial advancements in clinical trials and industrial applications. Compared to previous decades, stem cell therapies in China have experienced remarkable progress, with numerous companies advancing to the clinical research phase, indicating a robust overall development trajectory. Nonetheless, the considerable variability in the sources, types, and preparation processes of stem cell products contributes to the complexity of their therapeutic mechanisms and in vivo activities, which are more intricate than those of traditional pharmaceuticals. Consequently, stem cell therapies encounter several challenges in drug development, including issues related to safety, induction efficiency, the exploration of clinical translation processes, and elevated research and development costs, all of which may hinder the advancement of stem cell therapies. Nevertheless, numerous companies and research institutions are actively engaged in promoting progress within the stem cell domain. It is anticipated that, as the stem cell sector continues to evolve, these challenges will be addressed, ultimately serving as a crucial catalyst for meeting various unmet clinical needs and effecting transformative changes in human healthcare and other sectors.

Stem Cell Research & TherapyVol. 16(1)
Shenyang Pharmaceutical University (CN), The Fifth People’s Hospital of Suzhou (CN), China Medical University (CN)
National Natural Science Foundation of China, Department of Science and Technology of Liaoning Province
Openalex Percentile: Top 16%
Biomedical Ethics and Regulation
1.16
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.